IMR Press / FBL / Special Issues / 1409436476869365762

Conversion therapy for cancer and its imagery monitoring

Submission deadline: 31 December 2022
Special Issue Editors
Yu Guo
The First Affiliated Hospital of Sun Yat-Sen University
Interests: Targeted Nanomedicine; Molecular Imaging; Cancer Molecular Biology; Treatment of Liver Cancer; Individualized Therapy for Cancer
Shunli Shen
The First Affiliated Hospital of Sun Yat-Sen University
Interests: Basic and clinical research of liver cancer; Cancer Molecular Biology; Cancer Immunotherapy; Cancer targeted therapy
Ruo-Mi Guo
The Third Affiliated Hospital of Sun Yat-Sen University
Interests: Molecular Imaging; Radiological Diagnosis; Functional MRI; In vivo Tracking of Tumor or Stem Cell Treatment
Special Issue Information

Dear Colleagues,

In recent years, there has been an increasing demand for the therapeutic efficacy of previous single tumor treatment techniques such as surgery, interventional therapy, radiotherapy, chemotherapy and immunotherapy. In order to achieve a better outcome or to cure previously unresectable tumors, doctors now try to design conversion treatment plans based on individual characteristics of patients in clinical practice. Conversion therapy might achieve previously unimaginable good results. The exploration of conversion therapy is accompanied by a large number of attempts to develop new medicines (e.g. new nanomedicines, immunological agents, targeted agents), new techniques and devices (e.g. surgery, radiotherapy, interventional therapy), and individualized treatment schemes (e.g. sequencing technology). At the same time, there is a higher demand for the effectiveness of radiological examination during conversion therapy. The development in this field, including new molecular imaging techniques, new nano-contrast agents, and new MRI functional imaging methods, has also made great strides.

We warmly welcome research results in the fields as described above concerning diagnostic & therapeutic oncology and drug development.

Prof. Dr. Yu Guo, Prof. Dr. Shunli Shen and Prof. Dr. Ruo-Mi Guo

Guest Editors

Cancer Conversion Therapy
Anticancer Drug Development
Interventional Therapy
Molecular Functional Imaging
Individualized Therapy
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.

Back to top